Goodrich Katherine
SEC Form 4 insider trading activity
Goodrich Katherine has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Jun 17, 2026.
On the most recent filing, Goodrich Katherine is listed as Director at Tarsus Pharmaceuticals, Inc. Inside the rolling window, Goodrich Katherine reported no open-market purchases and 1 open-market sale totaling $183K in TARS.
Companies traded
Other insiders at TARS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$183K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Goodrich Katherine made?
Goodrich Katherine has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Goodrich Katherine trade?
Goodrich Katherine has filed SEC Form 4 disclosures for 1 company, including TARS.
When was Goodrich Katherine's most recent SEC Form 4 filing?
Goodrich Katherine's most recent SEC Form 4 filing on Tracefour is dated Jun 17, 2026.
What is Goodrich Katherine's total buy and sell value in the current window?
Inside the rolling retention window, Goodrich Katherine bought $0 and sold $183K based on SEC Form 4 filings.
What was Goodrich Katherine's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,954 TARS shares on 2026-06-15, worth $183K, per SEC Form 4 filings.